EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC 4.0

Adherence and Persistence to Pharmacotherapy in Patients with Heart Failure: A Nationwide Cohort Study, 2014–2020

Kristina Malene Ødegaard, Sandre Svatun Lirhus, Hans Olav Melberg, Jonas Hallén, Sigrun Halvorsen

ESC Heart Failure · 01.02.2023 · 10 (1) · 405-415

DOI: 10.1002/ehf2.14206 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift ESC Heart Failure, online erschienen am 20.10.2022. Verfasst von Kristina Malene Ødegaard und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Clinical Medicine, University of Oslo, Oslo, Norway. Hauptthemen laut MEDLINE: Angiotensin Receptor Antagonists, Angiotensin-Converting Enzyme Inhibitors, Heart Failure, Mineralocorticoid Receptor Antagonists. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Research Council of Norway, Novartis Norway AS, Norges Forskningsråd.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

We aimed to study initiation, adherence, and long-term persistence to beta-blockers (BB), renin–angiotensin system inhibitors (RASi), and mineralocorticoid receptor antagonists (MRA) in a nationwide cohort of patients with heart failure (HF).

Methods

Patients aged 18–80 years in Norway with a first diagnosis of HF from 2014 until 2020 that survived ≥30 days were identified from the Norwegian Patient Registry and linked to the Norwegian Prescription Database. We collected information about BB, RASi [angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARB), and angiotensin receptor-neprilysin inhibitors (ARNI)], and MRA. Dual HF therapy was defined as taking at least two out of three drug classes, whereas triple HF therapy was defined as taking all three. Initiation (time to initiation) and persistence (time to discontinuation using a grace period of 30 days) of HF drugs was calculated by the Kaplan–Meier method, followed to outcome of interest, death, or December 2020. One-year adherence was measured as proportion of days covered (PDC) using a cut-off at 80%. For adherence and persistence measurements, we allowed for maximum 60 days of stockpiling and switching within drug groups. We performed sensitivity analyses to test the robustness of our findings.

Results

Out of 54 899 patients included in the cohort, 75%, 69%, and 21% initiated a BB, RASi, and MRA, respectively, whereas 13% did not receive any. Dual and triple HF therapy was prescribed to 61% and 16%, respectively. The proportion of adherent patients during the first year following initiation was 83%, 81%, 84%, and 61% for BB, RASi, ARNI, and MRA, whereas 42% and 5% were adherent to dual and triple HF therapy, respectively. From 2 to 5 years following initiation, persistence decreased from 58% to 38%, 57% to 37%, and 31% to 15% for BB, RASi, and MRA, respectively. Within the RASi group, persistence was higher for ARNI than for ACEI and ARB. There were no major changes in either initiation or adherence of the drug classes from 2014 to 2019, except for an increase in initiation and adherence of MRA.

Conclusions

We found low adherence to dual and triple HF therapies in this nationwide cohort study of newly diagnosed HF patients. Efforts are needed to increase adherence and persistence to HF therapies into clinical practice, emphasizing maintenance of multiple drug therapies in patients with such an indication.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Angiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsHeart FailureMineralocorticoid Receptor AntagonistsDrug MonitoringHumansAdrenergic beta-AntagonistsAnti-Arrhythmia AgentsAntihypertensive AgentsCohort StudiesDiuretics

Stichwörter der Autor:innen

AdherenceGuideline-directed medical therapyHeart failurePDCPersistence

Substanzen

Adrenergic beta-AntagonistsAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsAnti-Arrhythmia AgentsAntihypertensive AgentsDiureticsMineralocorticoid Receptor Antagonists

Autor:innen und Institutionen

  • Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Novartis Norway AS, Oslo, Norway.
  • Institute of Health and Society, University of Oslo, Oslo, Norway.
  • Department of Community Medicine, UiT - The Arctic University of Norway, Tromsø, Norway.
  • Arxx Therapeutics, Oslo, Norway.
  • Department of Cardiology, Oslo University Hospital Ulleval, Oslo, Norway.

Förderung

  • Research Council of Norway
  • Novartis Norway AS
  • Norges Forskningsråd

Zitieren

APA

Ødegaard, K. M., Lirhus, S. S., Melberg, H. O., Hallén, J., & Halvorsen, S. (2023). Adherence and Persistence to Pharmacotherapy in Patients with Heart Failure: A Nationwide Cohort Study, 2014–2020. ESC Heart Failure, 10(1), 405-415. https://doi.org/10.1002/ehf2.14206

Vancouver

Ødegaard KM, Lirhus SS, Melberg HO, Hallén J, Halvorsen S. Adherence and Persistence to Pharmacotherapy in Patients with Heart Failure: A Nationwide Cohort Study, 2014–2020. ESC Heart Failure. 2023;10(1):405-415. doi:10.1002/ehf2.14206

BibTeX
@article{degaard2023,
  author = {Ødegaard, Kristina Malene and Lirhus, Sandre Svatun and Melberg, Hans Olav and Hallén, Jonas and Halvorsen, Sigrun},
  title = {Adherence and Persistence to Pharmacotherapy in Patients with Heart Failure: A Nationwide Cohort Study, 2014–2020},
  journal = {ESC Heart Failure},
  year = {2023},
  volume = {10},
  number = {1},
  pages = {405--415},
  doi = {10.1002/ehf2.14206}
}
Kostenlos starten →